Surgical safety and pathological outcome of perioperative PD-1 inhibitor in combination with chemotherapy for Siewert Ⅱ/Ⅲ locally advanced adenocarcinoma of gastroesophageal junction
10.3969/j.issn.1005-6483.2023.12.008
- VernacularTitle:化疗联合PD-1免疫检查点抑制剂新辅助治疗局部进展期Siewert Ⅱ/Ⅲ型食管胃结合部腺癌后行根治性手术的安全性及效果分析
- Author:
Ziming WANG
1
;
Haowen ZHANG
Author Information
1. 455000 河南省安阳市肿瘤医院外一科
- Keywords:
adenocarcinoma of gastroesophageal junction;
neoadjuvant therapy;
PD-1 inhibitor;
SOX;
surgical safety
- From:
Journal of Clinical Surgery
2023;31(12):1137-1140
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the surgical safety and pathological outcome of PD-1 inhibitor plus chemotherapy as neoadjuvant therapy for Siewert Ⅱ/Ⅲ locally advanced gastroesophageal junction adenocarcinoma.Methods 20 patients were recruited from January 2022 to December 2022,which conformed to Siewert Ⅱ/Ⅲ and c'T3-4N0M0 or cT2-4N+M0,and accepted at least two cycles of neoadjuvant regimen of PD-1 inhibitor plus chemotherapy before radical operation.While,23 patients,who accepted direct radical operation.,were seted as the matched group.The incidence of adverse events and serious adverse events in the neoadjuvant period were evaluated.The surgery safety,the postoperative recovery,the surgery complications rate and the pathological outcome were compared between the two groups.Results In terms of safety of preoperative therapy,17 patients(85％)undergoed adverse events,the incidence of serious adverse events was 30％.The operation time,intraoperative blood loss,lymph number harvested,time to start eating,postoperative days,and post operative mortality and morbidity between the two groups are all have no statistical differences.The pT stages was statistically lower than the matched group.In the neoadjuvant treatment group,the pathological complete response rate was 40％.Conclusion PD-1 inhibitor plus chemotherapy is a safe neoadjuvant therapy,and exhibits promising pathological response,in patients with Siewert Ⅱ/Ⅲ locally advanced AEG.
